KRAS and non-small cell lung carcinoma: In the CodeBreaK 200 study, a randomized, open-label, phase 3 trial (June 2020 to April 2021) of sotorasib (n=171) versus docetaxel (n=174) in the second-line setting and beyond of advanced NSCLC patients with KRAS G12C mutation, sotorasib significantly increased PFS (i.e., median PFS 5.6 months [95% CI, 4.3–7.8] vs. 4.5 months [3.0–5.7]; hazard ratio 0.66 [0.51–0.86]; p=0.0017) and exhibited a better safety profile (33).